PMV Pharmaceuticals, Inc.
PMVP
$1.10
$0.010.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -63.84% | 130.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.32% | 14.99% | |||
| Operating Income | 14.32% | -14.99% | |||
| Income Before Tax | 14.64% | -20.09% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | 24.19% | -19.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.19% | -19.63% | |||
| EBIT | 14.32% | -14.99% | |||
| EBITDA | 14.33% | -16.79% | |||
| EPS Basic | 24.40% | -19.07% | |||
| Normalized Basic EPS | 14.85% | -19.52% | |||
| EPS Diluted | 24.40% | -19.07% | |||
| Normalized Diluted EPS | 14.85% | -19.52% | |||
| Average Basic Shares Outstanding | 0.26% | 0.47% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||